Evaluation of the Long Term Efficacy and Tolerability of ART FILLER® Volume and Lips

The function of injectable fillers for the treatment of dermal contour deformities is to smooth dermal depressions formed by the loss of volume. These fillers (also known as soft tissue augmentation devices) can restore the age-related volume loss of the face, balance the disproportions or correct topographical anomalies. Art Filler® Volume and Art Filler Lips are two hyaluronic-based fillers. Both contain 0.3% lidocaine hydrochloride for its anaesthetic properties. The difference between the two devices lies in their viscosity, which must be adapted for the regions being treated and to restoring facial volumes. Midface for Art Filler® Volume and Lips for Art filler® Lips. On this background, a study is conducted to evaluate the long term efficacy and tolerability of Art Filler® Volume and Art Filler® Lips. It is a prospective, non-comparative, multicentre study with long term evaluation (18 months) of the tolerability and assessment of the efficacy of two devices containing hyaluronic acid intended for filling of lines and restoring volume to the face and lips.

The function of injectable fillers for the treatment of dermal contour deformities is to smooth dermal depressions formed by the loss of volume. These fillers (also known as soft tissue augmentation devices) can restore the age-related volume loss of the face, balance the disproportions or correct topographical anomalies. Art Filler® Volume and Art Filler Lips are two hyaluronic-based fillers. Both contain 0.3% lidocaine hydrochloride for its anaesthetic properties. The difference between the two devices lies in their viscosity, which must be adapted for the regions being treated and to restoring facial volumes. Midface for Art Filler® Volume and Lips for Art filler® Lips. On this background, a study is conducted to evaluate the long term efficacy and tolerability of Art Filler® Volume and Art Filler® Lips. It is a prospective, non-comparative, multicentre study with long term evaluation (18 months) of the tolerability and assessment of the efficacy of two devices containing hyaluronic acid intended for filling of lines and restoring volume to the face and lips.

Primary objective:

* Art Filler® Volume: To confirm the capacity of Art Filler® Volume to restore a midface volume 3 weeks after the first injection or after 6 weeks if a touch-up was performed at 3 weeks. For a given target area (right or left) volume restoration will be deemed to be satisfactory if the Medicis Midface Volume Scale (MMVS) score falls by at least 1 moint compared to the baseline score.
* Art Filler® Lips: To confirm the capacity of Art Filler® Lips to restore volume of the treated lip 3 weeks after the first injection or after 6 weeks if a touch-up was performed at 3 weeks. For each lip treated (upper or lower) volume restoration will be deemed to be satisfactory if the Medicis Lip Fullness Scale (MLFS) score falls by at least 1 point compared to the baseline score.

Eligibility Criteria:
Inclusion Criteria:

1. Adult subjects not under legal protection who have given their written agreement to take part.
2. Men or women, 19 years old or older with no upper limit.
3. Fitzpatrick phototype, I, II, III or IV.
4. Middle 1/3 of the face (cheeks/cheek pads): Score 3 or 4 (moderate to substantial loss of volume in the middle 1/3 of the face) on Medicis Midface Volume Scale (MMVS) AND/OR Lips: Score of 1 to 2 (very thin to thin lips) on the Medicis Lip Fullness Scale (MLFS)
5. Subjects seen at least 12 months after any aesthetic surgery procedure to the face.
6. Subjects at least 12 months from any corrective aesthetic facial injection (botulin in toxin or any filling agent) in the study regions, i.e. 1/3 of the midface and peri-oral/lip region.
7. Subjects who are members of a social security system.

Exclusion Criteria:

1. Subjects who do not meet the selection criteria.
2. Subjects participating in any other clinical study on the assessment of medicinal products or medical devices or subjects who are in the exclusion period following a clinical study.
3. Subjects who have received a facial injection/implantation of any non-resorbable filling agent.
4. Subjects with skin support devices (tension wires, gold wires or weave) in their face.
5. Subjects who have received laser or ultrasound medical treatment, deep chemical peeling or dermabrasion to the face during the previous 3 months or intending to undergo such a treatment to the face during the study.
6. Subjects with a known past history of hypertrophic, cheloid or dyschromic scarring.
7. Subjects with a past history of multiple severe allergies or anaphylactic shock.
8. Subjects with known hypersensitivity to any of the components of the study devices.
9. Subjects with porphyria.
10. Subjects with a past history of Streptococcal diseases (recurrent pharyngitis, acute articular rheumatic disease).
11. Subjects with hepatocellular impairment and coagulation disorders.
12. Subjects treated with medicinal products which reduce or inhibit liver metabolism.
13. Subjects with any acquired or congenital blood dyscrasia abnormality.
14. Subjects with cardiac conduction abnormalities.
15. Subjects with an episode of Herpes lesions on the face which have recovered within less than 4 weeks and with a contraindication to oral antiviral preventative treatment.
16. Subjects with facial scarring involving the injection regions.
17. Subjects receiving surgical orodental care and/or treatment for infection within 2 months.
18. Subjects receiving concomitant treatment (or treatment which has not been stopped for at least 3 months) with oral or injectable corticosteroids (inhaled corticosteroids and local corticosteroid therapy not involving the head or neck are permitted).
19. Subjects with concomitant treatment with an immunosuppressant or other chemotherapy treatment.
20. Subjects with a past history of radiotherapy to the head and neck within 6 months.
21. Subjects with a past history or autoimmune or connective tissue disease.
22. Subjects with an acute inflammatory reaction or bacterial or viral infection or seen within 1 month after the end of such an episode.
23. Pregnant or breast-feeding women (a urine pregnancy test will be performed before each injection).
24. Subjects suffering from epilepsy not controlled by treatment.
25. Subjects with a systemic or psychiatric disorder which could compromise their participation.
26. Receipt of an NSAID, or high dose vitamin C and/or E within one week.